# Special Issue

# T Cells in Hematologic Malignancies: Biology, Microenvironment, and Therapeutic Advances

### Message from the Guest Editor

We are pleased to invite you to contribute to this Special Issue, "T Cells in Hematologic Malignancies: Biology, Microenvironment, and Therapeutic Advances."T cells are key regulators of immune surveillance and therapeutic response in hematologic malignancies. The clinical success of CAR-T cell therapies and bispecific T cell engagers has transformed the management of lymphoid malignancies and multiple myeloma, while revealing new challenges in understanding T cell biology within the unique bone marrow and lymphoid microenvironments. Emerging insights also point to important roles for T cells in myeloid neoplasms such as acute myeloid leukemia and myelodysplastic syndromes. This Special Issue will highlight advances spanning basic mechanisms to translational and clinical applications. It welcomes original research and reviews on T cell biology, microenvironmental interactions, therapeutic innovation, and mechanisms of resistance. We look forward to receiving your contributions and to advancing the field together.

### **Guest Editor**

Maria Velegraki, MD, PhD

- 1. Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
- 2. Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA

### Deadline for manuscript submissions

16 September 2026



## Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/257888

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

